Oppenheimer & Co. Inc. Has $1.90 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Oppenheimer & Co. Inc. increased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 85.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 94,938 shares of the biotechnology company’s stock after acquiring an additional 43,836 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in ADMA Biologics were worth $1,898,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Sei Investments Co. lifted its holdings in ADMA Biologics by 176.0% in the first quarter. Sei Investments Co. now owns 393,481 shares of the biotechnology company’s stock valued at $2,597,000 after buying an additional 250,925 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of ADMA Biologics by 90.7% in the 1st quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after purchasing an additional 556,175 shares during the period. ProShare Advisors LLC boosted its position in shares of ADMA Biologics by 9.2% during the 1st quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company’s stock valued at $358,000 after purchasing an additional 4,570 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its stake in ADMA Biologics by 114.3% during the first quarter. CANADA LIFE ASSURANCE Co now owns 54,049 shares of the biotechnology company’s stock worth $357,000 after purchasing an additional 28,832 shares during the period. Finally, Shell Asset Management Co. bought a new stake in ADMA Biologics in the first quarter worth approximately $155,000. 75.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ADMA has been the subject of several recent analyst reports. Raymond James raised their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th. HC Wainwright boosted their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $19.04 on Monday. The stock has a market cap of $4.50 billion, a price-to-earnings ratio of 68.00 and a beta of 0.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The firm’s 50-day simple moving average is $18.54 and its 200 day simple moving average is $14.40.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same quarter last year, the company earned $0.01 EPS. As a group, research analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In other news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. This represents a 10.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of ADMA Biologics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $16.90, for a total value of $408,135.00. Following the sale, the chief operating officer now directly owns 449,088 shares of the company’s stock, valued at $7,589,587.20. This represents a 5.10 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 466,900 shares of company stock valued at $8,224,121. Corporate insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.